Average approval time reduced by 2.5-3.5 years. Breakthrough therapy designation usually increases valuation significantly. Takeover offers typically increase with breakthrough therapy designations.

However, a recent analysis of BTD denials by Woodcock 9 provides valuable insight into applications for BTD resulting in failure, as shown in Table 3. Of 86 denials in a broad range of indications not ...